StreetInsider.com News Articles

Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4

Tue, 21 Jul 2026 08:00:00 -0400

GERMANTOWN, Md., July 21, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced the Company will release second quarter 2026 financial results and provide business updates on Tuesday, August 4, 2026. The Company will host a conference call to discuss results that day at 4:30 PM ET.

Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4

Tue, 21 Jul 2026 08:00:00 -0400

Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4

Tue, 21 Jul 2026 08:00:00 -0400

Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4

Tue, 21 Jul 2026 08:00:00 -0400

Form 4 PRECIGEN, INC. For: Jun 29 Filed by: Thomasian Harry Jr.

Wed, 01 Jul 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260701/26722411.html

Form 4 PRECIGEN, INC. For: Jun 29 Filed by: Thomasian Harry Jr.

Wed, 01 Jul 2026 18:22:00 -0400

si-local-file:///var/storage/secattach/20260701/26722411.html

Form 4 PRECIGEN, INC. For: Jun 29 Filed by: Shah Rutul R

Wed, 01 Jul 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260701/26722409.html

Form 4 PRECIGEN, INC. For: Jun 29 Filed by: Shah Rutul R

Wed, 01 Jul 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260701/26722409.html

Form 4 PRECIGEN, INC. For: Jun 29 Filed by: Sabzevari Helen

Wed, 01 Jul 2026 18:19:00 -0400

si-local-file:///var/storage/secattach/20260701/26722403.html

Form 4 PRECIGEN, INC. For: Jun 29 Filed by: Sabzevari Helen

Wed, 01 Jul 2026 18:19:00 -0400

si-local-file:///var/storage/secattach/20260701/26722403.html

Form 144 PRECIGEN, INC. Filed by: Thomasian Harry Jr.

Wed, 01 Jul 2026 12:20:00 -0400

si-local-file:///var/storage/secattach/20260701/26719165.html

Form 144 PRECIGEN, INC. Filed by: Thomasian Harry Jr.

Wed, 01 Jul 2026 12:20:00 -0400

si-local-file:///var/storage/secattach/20260701/26719165.html

Form 144 PRECIGEN, INC. Filed by: Sabzevari Helen

Mon, 29 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260629/26706626.html

Form 144 PRECIGEN, INC. Filed by: Sabzevari Helen

Mon, 29 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260629/26706626.html

Form 144 PRECIGEN, INC. Filed by: Shah Rutul R

Mon, 29 Jun 2026 11:30:00 -0400

si-local-file:///var/storage/secattach/20260629/26704209.html

Form 144 PRECIGEN, INC. Filed by: Shah Rutul R

Mon, 29 Jun 2026 11:30:00 -0400

si-local-file:///var/storage/secattach/20260629/26704209.html

Form 144 PRECIGEN, INC. Filed by: Thomasian Harry Jr.

Mon, 29 Jun 2026 10:58:00 -0400

si-local-file:///var/storage/secattach/20260629/26703943.html

Form 144 PRECIGEN, INC. Filed by: Thomasian Harry Jr.

Mon, 29 Jun 2026 10:58:00 -0400

si-local-file:///var/storage/secattach/20260629/26703943.html

Form 8-K PRECIGEN, INC. For: Jun 18

Wed, 24 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260624/26685566.html

Form 8-K PRECIGEN, INC. For: Jun 18

Wed, 24 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260624/26685566.html

Precigen receives FDA orphan drug exclusivity for PAPZIMEOS through 2032

Mon, 15 Jun 2026 06:41:39 -0400

Precigen Inc. (NASDAQ: PGEN) received orphan drug exclusivity from the FDA for PAPZIMEOS, its treatment for recurrent respiratory papillomatosis (RRP), extending market protection through August 2032.

The exclusivity prevents FDA approval of similar drugs for RRP for seven years. RRP is a rare respiratory disease affecting fewer than 200,000 people in the United States, where patients typically undergo multiple surgeries annually to remove benign tumors in the respiratory tract.

PAPZIMEOS uses a modified adenovirus to train the immune system to target proteins in HPV 6 and HPV 11, which cause RRP. The drug is currently available commercially in the United States and

Precigen receives FDA orphan drug exclusivity for PAPZIMEOS through 2032

Mon, 15 Jun 2026 06:41:39 -0400

PAPZIMEOS uses a modified adenovirus to train the immune system to target proteins in HPV 6 and HPV 11, which cause RRP. The drug is currently available commercially in the United States and

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Mon, 15 Jun 2026 06:40:00 -0400

Meg Flippin, Benzinga Staff Writer

Data reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rare respiratory disease

GERMANTOWN, MD / ACCESS Newswire / June 15, 2026 / Precigen Inc. (NASDAQ:PGEN) has gained an important advantage in the marketing of its new treatment for adults with recurrent respiratory papillomatosis (RRP), a rare and debilitating disease of the respiratory tract.

The commercial-stage precision medicines company was just granted orphan drug exclusivity by the

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Mon, 15 Jun 2026 06:40:00 -0400

Meg Flippin, Benzinga Staff Writer

Data reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rare respiratory disease

The commercial-stage precision medicines company was just granted orphan drug exclusivity by the

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Thu, 11 Jun 2026 08:00:00 -0400

Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with RRP

GERMANTOWN, Md. and FORT WORTH, Texas, June 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients and the Recurrent Respiratory Papillomatosis Foundation (RRPF), today announced continued collaboration in recognition of the third annual International RRP Awareness Day.